 The study will be an open-label, single-institution, non-randomized, single-arm, Phase II study of pembrolizumab therapy in patients with advanced HCC. Patients will be treated in three-week cycles, with intravenous IV administration of pembrolizumab on day 1 of each 3-week cycle. Trial therapy will last until withdrawal of consent, disease progression andor unacceptable toxicity, whichever occurs first. 